Quantifying KRAS for Optimal Cancer Therapy
AssigneesExpression Pathology, Inc., NantOmics, LLC
InventorsFabiola CECCHI, Adele BLACKLER, Wei-Li LIAO, Todd HEMBROUGH, Daniel CATENACCI
Life of this patent
Estimating the term…
Abstract
Methods are provided for identifying whether a tumor will be responsive to treatment with an anti-EGFR agent. Specific protein fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in tumor cells collected from tumor tissue that was obtained from a cancer patient and compared to reference levels in order to determine if the lung cancer patient will positively respond to treatment with an anti-EGFR agent such as, for example, pamitumumab and/or erbitux.
Claims19
A method of treating a patient suffering from cancer comprising:
- (a) quantifying the level of a specified KRAS fragment peptide in a protein digest prepared from a tumor sample obtained from the patient and calculating the level of said KRAS peptide in said sample by selected reaction monitoring using mass spectrometry;
- (b) comparing the level of said KRAS fragment peptide to a reference level, and
- (c) treating the patient with a therapeutic regimen comprising an effective amount of at least one anti-EGFR agent when the level of the KRAS fragment peptide is lower than said reference level, and
- (d) treating the patient with a therapeutic regimen that does not comprise an effective amount of at least one anti-EGFR agent when the level of the KRAS fragment peptide is above said reference level.
4-6. (canceled)
The method of claim 14, wherein the tumor sample is formalin fixed solid tissue.
The method of claim 15, wherein the tissue is paraffin embedded tissue.
Dependencies are inferred from the claim text.